JOHN KIRKWOOD to Recombinant Fusion Proteins
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Recombinant Fusion Proteins.
Connection Strength
1.143
-
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
Score: 0.503
-
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011 Oct 15; 17(20):6574-81.
Score: 0.307
-
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2023 Dec 14; 389(24):2256-2266.
Score: 0.178
-
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 09 23; 385(13):1196-1206.
Score: 0.154